EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Establishment of epidemiological cut-off values of etimicin: a new fourth-generation aminoglycoside, against Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis , Pseudomonas aeruginosa , Acinetobacter baumannii and Staphylococcus aureus

Ge Zhang, Zhengyu Luo iD, Qiwen Yang iD, Wei Kang, Jingjia Zhang, Jin Li, Tong Wang, Jie Lin, Yunsong Yu iD, Chuyue Zhuo, Chao Zhuo, Qihui Wang und 6 weitere

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkae414 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Ge Zhang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing,…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Aminoglycosides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National High Level Hospital Clinical Research Funding, Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To determine the epidemiological cut-off (ECOFF) values of etimicin against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus.

Methods

We selected 1500 isolates from five hospitals throughout five cities in China spanning from January 2018 to December 2021 in the study. Minimal inhibit concentrations (MICs) of etimicin were determined using the broth microdilution method. ECOFFs of etimicin against six species were calculated using ECOFFinder software and visual estimation following EUCAST principles.

Results

MICs of etimicin were distributed from 0.064 to >128 mg/L for S. aureus, from 0.125 to >128 mg/L for P. aeruginosa, from 0.25 to >128 mg/L for K. pneumoniae, P. mirabilis and A. baumannii, and from 0.5 to >128 mg/L for E. coli. The MIC ECOFF of etimicin was 2 mg/L for K. pneumoniae, 8 mg/L for E. coli and P. mirabilis, 16 mg/L for P. aeruginosa and A. baumannii, and the tentative ECOFF (TECOFF) of etimicin was 2 mg/L for S. aureus.

Conclusions

(T)ECOFFs of etimicin against E. coli, K. pneumoniae, P. mirabilis, P. aeruginosa, A. baumannii and S. aureus were determined, which will be helpful to differentiate wild-type strains.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsAminoglycosidesMicrobial Sensitivity TestsHumansProteus mirabilisPseudomonas aeruginosaStaphylococcus aureusKlebsiella pneumoniaeAcinetobacter baumanniiEscherichia coliChinaHospitals

Substanzen

Anti-Bacterial AgentsAminoglycosides

Autor:innen und Institutionen

  • Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
  • Graduate School, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Clinical Laboratory, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.
  • Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.
  • Department of Infectious Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Department of Laboratory Medicine, The First Hospital of China Medical University, Shenyang, Liaoning, China.

ORCID-Profile: Zhengyu Luo, Qiwen Yang, Yunsong Yu

Förderung

  • National High Level Hospital Clinical Research Funding
  • Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences

Zitieren

APA

Zhang, G., Luo, Z., Yang, Q., Kang, W., Zhang, J., Li, J., Wang, T., Lin, J., Yu, Y., Zhuo, C., Zhuo, C., Wang, Q., Chu, Y., Chen, Z., Sun, Z., Guo, D., Zhang, L., & Xu, Y. (2025). Establishment of epidemiological cut-off values of etimicin: a new fourth-generation aminoglycoside, against Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis , Pseudomonas aeruginosa , Acinetobacter baumannii and Staphylococcus aureus. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae414

Vancouver

Zhang G, Luo Z, Yang Q, Kang W, Zhang J, Li J, et al. Establishment of epidemiological cut-off values of etimicin: a new fourth-generation aminoglycoside, against Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis , Pseudomonas aeruginosa , Acinetobacter baumannii and Staphylococcus aureus. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkae414

BibTeX
@article{Zhang2025,
  author = {Zhang, Ge and Luo, Zhengyu and Yang, Qiwen and Kang, Wei and Zhang, Jingjia and Li, Jin and Wang, Tong and Lin, Jie and Yu, Yunsong and Zhuo, Chuyue and Zhuo, Chao and Wang, Qihui and Chu, Yunzhuo and Chen, Zhongju and Sun, Ziyong and Guo, Dan and Zhang, Li and Xu, Yingchun},
  title = {Establishment of epidemiological cut-off values of etimicin: a new fourth-generation aminoglycoside, against Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis , Pseudomonas aeruginosa , Acinetobacter baumannii and Staphylococcus aureus},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkae414}
}
Kostenlos starten →